Get the Stockscreener App
3.04
3.05%
0.09
After Hours:
2.90
-0.14
-4.61%
Dermata Therapeutics Inc stock is traded at $3.04, with a volume of 48,514.
It is up +3.05% in the last 24 hours and down -32.14% over the past month.
Dermata Therapeutics Inc is a late-stage medical dermatology company focused on identifying, developing, and commercializing pharmaceutical product candidates for the treatment of medical skin diseases and aesthetic applications. Its two product candidates, XYNGARI (formerly known as DMT310) and DMT410, incorporate its proprietary, multifaceted, Spongilla technology to topically treat a variety of dermatological conditions. Its Spongilla technology platform will enable to development and formulation of singular and combination products that can target topical delivery of chemical compounds into the dermis for maximum treatment effect for a variety of inflammatory skin diseases. Dermata announced positive Phase 3 data from its STAR-1 clinical trial in March 2025.
See More
Previous Close:
$2.95
Open:
$3.0591
24h Volume:
48,514
Relative Volume:
0.39
Market Cap:
$2.07M
Revenue:
-
Net Income/Loss:
$-11.27M
P/E Ratio:
-0.142
EPS:
-21.4132
Net Cash Flow:
$-9.40M
1W Performance:
-11.11%
1M Performance:
-32.14%
6M Performance:
-65.14%
1Y Performance:
-77.31%
1-Day Range:
$2.90
$3.0591
1-Week Range:
$2.90
$3.4385
52-Week Range:
$2.90
$23.70
Dermata Therapeutics Inc Stock (DRMA) Company Profile
Name
Dermata Therapeutics Inc
Sector
Industry
Phone
(858)-223-0882
Address
3525 DEL MAR HEIGHTS RD., #322, SAN DIEGO
Compare DRMA with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
DRMA
Dermata Therapeutics Inc
|
3.04 | 2.01M | 0 | -11.27M | -9.40M | -21.41 |
|
VRTX
Vertex Pharmaceuticals Inc
|
409.47 | 105.61B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
657.53 | 67.99B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
442.70 | 58.19B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
854.65 | 52.40B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
189.70 | 39.60B | 447.02M | -1.18B | -906.14M | -6.1812 |
Dermata Therapeutics Inc Stock (DRMA) Latest News
Dermata Therapeutics Increases Stock Offering by $1.79M - TipRanks
Can Dermata Therapeutics Inc. stock sustain market leadershipJuly 2025 Drop Watch & Low Drawdown Trading Techniques - newser.com
Tools to monitor Dermata Therapeutics Inc. recovery probabilityMarket Trend Report & Community Verified Watchlist Alerts - newser.com
How to manage a losing position in Dermata Therapeutics Inc.2025 Top Gainers & Step-by-Step Trade Execution Guides - newser.com
Has Dermata Therapeutics Inc. formed a bullish divergenceRisk Management & Risk Managed Trade Strategies - newser.com
Heatmap analysis for Dermata Therapeutics Inc. and competitorsNew Guidance & Free Expert Approved Momentum Trade Ideas - newser.com
Intraday pattern recognizer results for Dermata Therapeutics Inc. Equity WarrantBear Alert & Safe Capital Growth Stock Tips - newser.com
Institutional scanner results for Dermata Therapeutics Inc. Equity WarrantPortfolio Growth Summary & Daily Technical Stock Forecast Reports - newser.com
Relative strength of Dermata Therapeutics Inc. in sector analysisQuarterly Trade Report & Proven Capital Preservation Methods - newser.com
What data driven models say about Dermata Therapeutics Inc.’s futureTrade Exit Summary & Reliable Price Breakout Alerts - newser.com
Can Dermata Therapeutics Inc. Equity Warrant stock resist market sell offs2025 Macro Impact & Risk Adjusted Buy/Sell Alerts - newser.com
Is Dermata Therapeutics Inc. stock a buy on dips2025 Trading Volume Trends & Daily Growth Stock Tips - newser.com
Order flow analysis tools used on Dermata Therapeutics Inc.2025 Retail Activity & Real-Time Volume Triggers - newser.com
Visualizing Dermata Therapeutics Inc. stock with heatmapsJuly 2025 Update & Technical Buy Zone Confirmation - newser.com
How Dermata Therapeutics Inc. Equity Warrant stock benefits from tech adoptionJuly 2025 Summary & Verified Chart Pattern Signals - fcp.pa.gov.br
Risk adjusted return profile for Dermata Therapeutics Inc. analyzedJuly 2025 Drop Watch & Accurate Intraday Trading Signals - newser.com
How strong is Dermata Therapeutics Inc. stock revenue growthEarnings Miss & Fast Exit and Entry Strategy Plans - fcp.pa.gov.br
Can technical indicators confirm Dermata Therapeutics Inc.’s reversalJuly 2025 Macro Moves & Stepwise Trade Signal Implementation - newser.com
Trend analysis for Dermata Therapeutics Inc. Equity Warrant this weekProduct Launch & High Win Rate Trade Alerts - newser.com
Why Dermata Therapeutics Inc. stock is trending among retail tradersTrade Signal Summary & Safe Entry Trade Signal Reports - newser.com
Analyzing drawdowns of Dermata Therapeutics Inc. with statistical toolsWatch List & Safe Capital Investment Plans - newser.com
How to use Fibonacci retracement on Dermata Therapeutics Inc.2025 Market Trends & Long-Term Growth Stock Strategies - newser.com
What valuation multiples suggest for Dermata Therapeutics Inc. Equity Warrant stockJuly 2025 Levels & Real-Time Buy Signal Alerts - newser.com
What hedge fund activity signals for Dermata Therapeutics Inc. Equity Warrant stockJuly 2025 Market Mood & Fast Exit and Entry Strategy Plans - newser.com
How Dermata Therapeutics Inc. Equity Warrant stock performs in high volatility marketsInflation Watch & AI Enhanced Trade Execution Alerts - fcp.pa.gov.br
Published on: 2025-11-05 21:08:02 - newser.com
Statistical indicators supporting Dermata Therapeutics Inc.’s strengthWeekly Loss Report & Free Low Drawdown Momentum Trade Ideas - newser.com
Is Dermata Therapeutics Inc. Equity Warrant building a consolidation baseJuly 2025 Trade Ideas & Safe Capital Growth Stock Tips - newser.com
What Fibonacci levels say about Dermata Therapeutics Inc. reboundMarket Growth Review & Detailed Earnings Play Strategies - newser.com
Applying Elliott Wave Theory to Dermata Therapeutics Inc.July 2025 Outlook & Consistent Profit Alerts - newser.com
Is Dermata Therapeutics Inc. stock a bargain at current levelsJuly 2025 Movers & Comprehensive Market Scan Insights - newser.com
Dermata Therapeutics Inc Stock (DRMA) Financials Data
Revenue
Net Income
Cash Flow
EPS
5.44%
0.70%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):